OncRef

Clinical Trial: NCT02486718

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Hoffmann-La Roche
Information Provided By:Hoffmann-La Roche
Last Update Posted:2026-09-30

Study Overview

Brief Summary

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.

Official Title

A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

Conditions

Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Atezolizumab
  • Drug: Cisplatin
  • Drug: Vinorelbine
  • Drug: Docetaxel
  • Drug: Gemcitabine
  • Drug: Pemetrexed

Other Study ID Numbers

  • GO29527
  • 2014-003205-15
  • 2023-505981-26-00
  • 2023
  • 2014

Start Date (Actual)

2015-10-31

Primary Completion Date (Actual)

2024-01-26

Study Completion Date (Actual)

2026-08-26

Enrollment (Actual)

1280

Study Type

Interventional

Phase

Phase 3